News & Updates

New drug applications approved by US FDA as of 16-30 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

For individuals with type 2 diabetes mellitus (T2DM), the earlier the age at diagnosis, the higher the likelihood of subsequent coronary heart disease (CHD), stroke, cancer, and all-cause death, as shown in a study.

Racial/ethnic and socioeconomic disparities exist in the treatment of individuals with alcohol use disorder (AUD), a study has found.

Testosterone replacement therapy (TRT) has the potential to be an effective adjunct treatment in the rehabilitation of critically ill patients with intensive care unit (ICU)-associated weakness (AW) and hospital-associated deconditioning (HAD), according to a Singapore study.

Use of tirzepatide results in better glycaemic control when compared with semaglutide, as shown by improved fasting glucose and glucose excursion control brought about by improvements in insulin secretion rate (ISR), insulin sensitivity, and glucagon suppression, according to a study.

People with cognitive frailty are at increased risk of falls, but the good news is that exercise helps improve physical function and reduce this risk, according to a study.

A single subcutaneous injection of benralizumab, administered alone or in combination with glucocorticoids, helps minimize treatment failure and improve symptoms in patients with an eosinophilic exacerbation of asthma or chronic obstructive pulmonary disorder (COPD), as shown in the phase II ABRA trial.